Rafael Bayarri Olmos, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Education & Training
- PhD
- Copenhagen University, Faculty of Health and Medical Sciences, PhD degree in Molecular Immunology (2018)
- MSc
- Copenhagen University, Faculty of Science, Master's degree in Biotechnology (2013)
- BSc
- University of Leon, Faculty of Biology and Biotechnology, 5-year degree in Biotechnology (2011)
Research
Copy Link
Overview
Public Health Interests
COVID-19; Emerging Infectious Diseases; Immunology; Pharmaceuticals and Medical Devices; Respiratory Disease/Infections; Vaccines; Viruses
ORCID
0000-0003-3202-9679- View Lab Website
Iwasaki lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rafael Bayarri Olmos's published research.
Publications Timeline
A big-picture view of Rafael Bayarri Olmos's research output by year.
Akiko Iwasaki, PhD
Andrew J. Hudak
Charalampia Koutsioumpa, MD, PhD
Christopher A Baker, PhD
Claire S. Laxton, PhD
Dong-il Kwon
38Publications
1,722Citations
Publications
2026
Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.
Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Sci Immunol 2026, 11: eaea6419. PMID: 42319912, DOI: 10.1126/sciimmunol.aea6419.Peer-Reviewed Original ResearchThis study investigates a novel vaccine strategy using BEACONs, a mucosal adjuvant, to enhance localized immunity and protect against genital herpes by boosting tissue-resident T cells and antibodies.
2023
Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody
Cyranka L, Mariegaard I, Skjødt M, Bayarri-Olmos R, Mollnes T, Garred P, Rosbjerg A. Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody. Journal Of Innate Immunity 2023, 15: 836-849. PMID: 37952515, PMCID: PMC10691831, DOI: 10.1159/000535084.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsC5a receptor 1C5aR1 inhibitionPolymorphonuclear leukocytesComplement C5a receptor 1Receptor 1Monoclonal antibodiesWhole bloodActivation markers CD11bIsolated polymorphonuclear leukocytesPotential therapeutic candidateInflammatory disease treatmentWhole blood modelCalcium flux assaysCell-binding studiesMouse monoclonal antibodyC5a-C5aR1Marker CD11bTherapeutic candidateHuman whole bloodC5aCalcium fluxComplement systemC5aR1Hybridoma clonesDisease treatmentDiverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands
Petersen M, Pérez-Alós L, Kongsstovu S, Eliasen E, Hansen C, Larsen S, Hansen J, Bayarri-Olmos R, Fjallsbak J, Weihe P, Garred P. Diverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands. Microbiology Spectrum 2023, 11: e00865-23. PMID: 37909772, PMCID: PMC10714973, DOI: 10.1128/spectrum.00865-23.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsT cell responsesOmicron infectionHumoral responseUnvaccinated individualsImmune responseRobust T cell responsesSARS-CoV-2 Omicron variantPositive T-cell responsesDetectable humoral responseLow humoral responseLower humoral immune responseT cell immunityCellular immune responsesHumoral immune responsePrior vaccinationThird doseHumoral immunityImmune evasionOmicron variantInfectionInfection statusImmunityVaccinationNational studyResponseMAP‐2:CD55 chimeric construct effectively modulates complement activation
González‐del‐Barrio L, Pérez‐Alós L, Cyranka L, Rosbjerg A, Nagy S, Prohászka Z, Garred P, Bayarri‐Olmos R. MAP‐2:CD55 chimeric construct effectively modulates complement activation. The FASEB Journal 2023, 37: e23256. PMID: 37823685, DOI: 10.1096/fj.202300571r.Peer-Reviewed Original ResearchCitationsAltmetricDistinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
Jarlhelt I, Pérez-Alós L, Bayarri-Olmos R, Hansen C, Petersen M, Weihe P, Armenteros J, Madsen J, Nielsen J, Hilsted L, Iversen K, Bundgaard H, Nielsen S, Garred P. Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies. Microbiology Spectrum 2023, 11: e01796-23. PMID: 37738355, PMCID: PMC10580960, DOI: 10.1128/spectrum.01796-23.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSARS-CoV-2 infectionLong-term humoral immunitySARS-CoV-2 IgCOVID-19 vaccineInfection-induced immunityAntibody responseReceptor-binding domainSARS-CoV-2Viral spike proteinHumoral immunityImmune responseSARS-CoV-2 antibody responseInfected individualsInfection-induced immune responsesReceptor-binding domain antibodiesSpecific IgLong-term immune responseDurability of immunitySpike proteinProtective antibody responsesSandwich ELISACOVID-19 infectionGeneralized mixed modelNew significant increaseS proteinPrevious immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Pérez-Alós L, Hansen C, Almagro Armenteros J, Madsen J, Heftdal L, Hasselbalch R, Pries-Heje M, Bayarri-Olmos R, Jarlhelt I, Hamm S, Møller D, Sørensen E, Ostrowski S, Frikke-Schmidt R, Hilsted L, Bundgaard H, Nielsen S, Iversen K, Garred P. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nature Communications 2023, 14: 5624. PMID: 37699890, PMCID: PMC10497567, DOI: 10.1038/s41467-023-41342-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune responseImmune imprintingOmicron infectionIgA responsesPrimary infectionSARS-CoV-2 immune responseSARS-CoV-2 infectionT cell immune responsesBreakthrough infection riskRobust humoral responseT cell responsesBNT162b2 vaccineHybrid immunityBooster vaccinationPrevious immunityVaccinated individualsHumoral responseLow IgGViral exposurePrevious infectionSubsequent reinfectionHigh riskVaccinationOmicron variantFuture infectionsRevaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C, Thomsen M, Andersen J, Jensen J, Bayarri-Olmos R, Garred P, Hermansen M, Johannsen A, Larsen M, Mistegaard C, Mikkelsen S, Nielsen L, Olesen R, Pérez-Alós L, Vils S, Szabados F, Søgaard O, Tolstrup M, Erikstrup C, Hauge E, Troldborg A. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients. Clinical And Experimental Rheumatology 2023, 42: 157-165. PMID: 37877429, DOI: 10.55563/clinexprheumatol/orpp04.Peer-Reviewed Original ResearchCitationsConceptsT cell responsesDetectable antibody responseBlood donorsSARS-CoV-2Antibody responseB cellsRheumatic diseasesCOVID-19 vaccine responsesSARS-CoV-2 antibodiesCOVID-19 mRNA vaccinesRevaccination of patientsSystemic lupus erythematosusB cell levelsCOVID-19 vaccinationPercent of casesDetectable serological responsesSARS-CoV-2 spike proteinAntibody class switchRD cohortLupus erythematosusVaccine responsesAntibody levelsRheumatoid arthritisSpecific IgGMRNA vaccinesShort-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
Madsen J, Holm B, Pérez-Alós L, Bayarri-Olmos R, Rosbjerg A, Fogh K, Pries-Heje M, Møller D, Hansen C, Heftdal L, Hasselbalch R, Hamm S, Frikke-Schmidt R, Hilsted L, Nielsen S, Iversen K, Bundgaard H, Garred P. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination. Microbiology Spectrum 2023, 11: e04947-22. PMID: 36877077, PMCID: PMC10101069, DOI: 10.1128/spectrum.04947-22.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSARS-CoV-2Salivary immunityIgG levelsBNT162b2 vaccinationFirst vaccinationSARS-CoV-2-infected individualsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 vaccinationSARS-CoV-2 IgGSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Prospective observational studyTime pointsSerum IgG levelsHigher IgG levelsSyndrome coronavirus 2Copenhagen University HospitalEffect of vaccinationHealth care professionalsBNT162b2 vaccineHybrid immunitySystemic vaccinationDetectable IgGSalivary IgG
2022
Enzyme-Linked Immunosorbent Assay for Activation of the Classical Complement Pathway by Plasmodium falciparum-Infected Erythrocyte Surface Antigen-Specific Antibodies
Larsen M, Bayarri-Olmos R, Garred P, Hviid L. Enzyme-Linked Immunosorbent Assay for Activation of the Classical Complement Pathway by Plasmodium falciparum-Infected Erythrocyte Surface Antigen-Specific Antibodies. Methods In Molecular Biology 2022, 2470: 673-678. PMID: 35881382, DOI: 10.1007/978-1-0716-2189-9_50.ChaptersCitationsAltmetricMeSH Keywords and ConceptsConceptsClassical complement pathwayComplement pathwayAntigen-specific antibodiesInnate immune systemEnzyme-linked immunosorbentErythrocyte surface antigenAntibody titer determinationSurface antigenImmune systemComplement cascadeImmunosorbent assayMonoclonal antibodiesBiological cascadeAntibodiesTiter determinationActivationPathwayAntigenImmunosorbentELISALectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19
Götz M, Skjoedt M, Bayarri-Olmos R, Hansen C, Pérez-Alós L, Jarlhelt I, Benfield T, Rosbjerg A, Garred P. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19. Journal Of Innate Immunity 2022, 15: 122-135. PMID: 35816998, PMCID: PMC10643890, DOI: 10.1159/000525508.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 patientsMASP-2 concentrationsHealthy controlsComplement activationConvalescent COVID-19 patientsNovel mouse monoclonal antibodyCOVID-19 pathophysiologyC-reactive proteinSandwich ELISAMASP-2Coronavirus disease 2019COVID-19Serine protease 2Downstream complement activationTerminal complement complexMouse monoclonal antibodyInflammatory markersConvalescent samplesMannose-binding lectinLectin complement pathwayDisease 2019Ficolin-3PatientsPossible associationFicolin-2
Get In Touch
Copy Link